V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity

HIV-1感染中V2靶向疫苗样抗体鉴定出一个具有广泛ADCC活性的额外K169结合轻链基序

阅读:4
作者:Charmaine van Eeden ,Constantinos Kurt Wibmer ,Cathrine Scheepers ,Simone I Richardson ,Molati Nonyane ,Bronwen Lambson ,Nonhlanhla N Mkhize ,Balakrishnan Vijayakumar ,Zizhang Sheng ,Sherry Stanfield-Oakley ,Jinal N Bhiman ,Valerie Bekker ,Tandile Hermanus ,Batsirai Mabvakure ,Arshad Ismail ,M Anthony Moody ,Kevin Wiehe ,Nigel Garrett ,Salim Abdool Karim ,Heini Dirr ,Manuel A Fernandes ,Yasien Sayed ,Lawrence Shapiro ,Guido Ferrari ,Barton F Haynes ,Penny L Moore ,Lynn Morris

Abstract

Antibodies that bind residue K169 in the V2 region of the HIV-1 envelope correlated with reduced risk of infection in the RV144 vaccine trial but were restricted to two ED-motif-encoding light chain genes. Here, we identify an HIV-infected donor with high-titer V2 peptide-binding antibodies and isolate two antibody lineages (CAP228-16H/19F and CAP228-3D) that mediate potent antibody-dependent cell-mediated cytotoxicity (ADCC). Both lineages use the IGHV5-51 heavy chain germline gene, similar to the RV144 antibody CH58, but one lineage (CAP228-16H/19F) uses a light chain without the ED motif. A cocrystal structure of CAP228-16H bound to a V2 peptide identified a IGLV3-21 gene-encoded DDxD motif that is used to bind K169, with a mechanism that allows CAP228-16H to recognize more globally relevant V2 immunotypes. Overall, these data further our understanding of the development of cross-reactive, V2-binding, antiviral antibodies and effectively expand the human light chain repertoire able to respond to RV144-like immunogens.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。